{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-368296","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2026-08-26T20:05:57+00:00","discovered_at":"2026-08-26T20:07:03.883147+00:00","generated_at":"2026-08-26T20:07:08.443675+00:00","sec_items":["4.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Inhibikase dismisses CohnReznick, appoints Deloitte as new auditor","bullets":["Dismissed CohnReznick effective Aug 21, 2026; no disagreements on accounting principles or practices.","Appointed Deloitte & Touche as independent auditor for FY2026, effective immediately after dismissal.","CohnReznick's audit reports for FY2024 and FY2025 were unqualified; no adverse or modified opinions.","Material weakness in internal control over financial reporting disclosed in Q2 2024 was remediated by Q3 2024.","CohnReznick letter to SEC dated Aug 26, 2026 filed as Exhibit 16.1."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-368296","json":"https://secwatch.observer/filing/0001193125-26-368296.json","markdown":"https://secwatch.observer/filing/0001193125-26-368296.md","text":"https://secwatch.observer/filing/0001193125-26-368296.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526368296/0001193125-26-368296-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526368296/d904831d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-26T20:07:08.443675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}